Moyamoya Disease with Aggressive Clinical Course in Infants for Safety and Healthy Growth Study
Not Applicable
Recruiting
- Conditions
- moyamoya disease
- Registration Number
- JPRN-UMIN000040169
- Lead Sponsor
- niversity of Toyama
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1) informed consent was not obtained 2) doctor-in-charge did not accept the enrollment
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of following events in infantile moyamoya disease (<4 years old) 1) stroke before bypass surgery 2) disease progression 3) perioperative complications 4) repeat bypass for ACA/PCA area 5) any death 6) poor functional outcome (mRS=3-5) 7) poor intellectual outcome (FSIQ<60)
- Secondary Outcome Measures
Name Time Method Incidence of flooding events in infantile moyamoya disease (<4 years old) 1) anti platelet 2) postoperative anemia 3) disease stage and moyamoya vessels at the onset 4) cerebral infarct at the onset 5) increase of cerebral infarct during follow-up period
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms drive aggressive moyamoya disease progression in infants per JPRN-UMIN000040169?
How does MACINTOSH Study compare surgical revascularization vs. conservative management for infant moyamoya disease?
Which biomarkers correlate with cerebral blood flow stability in JPRN-UMIN000040169 moyamoya disease cohort?
What adverse events are associated with pediatric moyamoya disease monitoring in the MACINTOSH observational trial?
Are antiplatelet agents or neuroprotective drugs evaluated as adjuncts in JPRN-UMIN000040169 moyamoya disease management?